| Company | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Rapport Therapeutics, Inc. | Chief Medical Officer | Common Stock | 197,426 | $1,970,311 | $9.98 | 06 Jun 2024 | Direct |
| Rapport Therapeutics, Inc. | Chief Medical Officer | Stock Option (Right to Buy) | 123,818 | 06 Jun 2024 | Direct | ||
| ZOGENIX, INC. | EVP & Chief Medical Officer | Common Stock | 0 | $26.04 | 07 Mar 2022 | Direct | |
| ZOGENIX, INC. | EVP & Chief Medical Officer | Restricted Stock Units | 0 | 07 Mar 2022 | Direct | ||
| ZOGENIX, INC. | EVP & Chief Medical Officer | Stock Option (Right to Buy) | 0 | $26.09 | 07 Mar 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Role | Filing Time |
|---|---|---|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | 06 Jun 2024 | 1 | $0 | 4 | Chief Medical Officer | 10 Jun 2024, 19:44 |
| RAPP | Rapport Therapeutics, Inc. | 06 Jun 2024 | 0 | $0 | 3 | Chief Medical Officer | 06 Jun 2024, 19:07 |
| /report/000089924322010297-galer-bradley-s-2022-03-07 | ZOGENIX, INC. | 07 Mar 2022 | 10 | $0 | 4 | EVP & Chief Medical Officer | 09 Mar 2022, 18:08 |
| /report/000137515121000087-galer-bradley-s-2021-08-09 | ZOGENIX, INC. | 09 Aug 2021 | 1 | $0 | 4 | EVP/Chief Medical Officer | 11 Aug 2021, 21:22 |